CSL today announced that it has completed the acquisition of Vifor Pharma, a process which had been behind schedule due to delayed approvals. On 2 August 2022, CSL finally received all the regulatory clearances and, hence, the acquisition was completed on 9 August 2022. CSL will now apply for the delisting of Vifor’s shares from the Swiss Exchange.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
End of coverage
- Published:
10 Aug 2022 -
Author:
Anas PATEL -
Pages:
2
CSL today announced that it has completed the acquisition of Vifor Pharma, a process which had been behind schedule due to delayed approvals. On 2 August 2022, CSL finally received all the regulatory clearances and, hence, the acquisition was completed on 9 August 2022. CSL will now apply for the delisting of Vifor’s shares from the Swiss Exchange.